Introduction {#Sec1}
============

The ureteral access sheath (UAS) has been developed on the same concept as AMPLATZ sheath for percutaneous nephrolithotomy, i.e., to allow direct access to the kidney and to decrease the intra-renal pressure during upper-tract endourological procedures. It has become increasingly popular as it offers a number of potential advantages including facilitation of access to the renal collecting systems, multiple entry and reentry, decreased intra-renal pressure, and improved drainage around the scope \[[@CR1]--[@CR5]\]. The UAS has the added advantage of allowing passive elimination of small stone fragments generated during laser fragmentation with the exit of irrigation fluid. Nevertheless, the use of the UAS can itself cause damage to the ureter by over distension which compromises ureteral blood flow, resulting in ureteral ischemia \[[@CR6]\] or direct damage to the ureter during the insertion of the UAS \[[@CR7]\].

The CROES initiated the Ureteroscopy (URS) Global Study to establish a prospective global database to examine the worldwide use of URS and determine factors affecting outcome. In the currently presented study, inverse-probability-weighted regression adjustment (IPWRA) is used to describe differences in stone-free rate (SFR) of patients who underwent URS treatment for their renal stones, with or without the use of a UAS.

Patients and methods {#Sec2}
====================

Study population {#Sec3}
----------------

The URS Global Study is a prospective, observational, international, multicenter study with data collected on consecutive patients treated with URS over a 1-year period at each participating center. The overall study period was from January 2010 until October 2012. Centers were asked to treat patients according to their local protocols. Institutional Research Board (IRB) or Institutional Ethics Committee approval was obtained by all participating centers before the start of the study. If IRB was not needed, the centers followed the protocol according the rules of Good Clinical Practice.

Patients who were eligible for inclusion in the present analysis were those who were candidates for flexible URS for renal stones as a primary treatment or after failure of a previous treatment and aged ≥18 years. No specific exclusion criteria were applied. Details of treatment including secondary treatment and patient follow-up have been described previously \[[@CR8]\].

Assessment {#Sec4}
----------

Data were encrypted and collected electronically through a web-based Web site: [www.croesoffice.org](http://www.croesoffice.org) and held in a central database at the CROES office. Data included patient epidemiological characteristics, calculus specification, type of treatment, and postoperative outcomes and complications. Stone burden was calculated as the sum of all stone sizes (length × width × 0.25 × 3.14159). The classification of a patient being stone free (SFR) was based on the absence of stones or fragments \>1 mm. Operating time was defined as the time from the insertion of the endoscope until the insertion of a bladder catheter. Treatment failure was defined as stone still in situ, remaining stone fragments \>1 mm, and failed access. Treatment success was defined as a patient free of stones \>1 mm.

Confounders {#Sec5}
-----------

Preoperative possible confounders were body mass index (BMI), age, gender, stone location, stone size, stone burden, American Society of Anesthesiologists (ASA) score, preoperative stent placement, anticoagulant and antibiotics use, comorbidities such as diabetes, cardiovascular disease (CVD), prednisone use, Crohn's disease, renal congenital abnormalities, a solitary kidney, case volume and academic status of the operating center. Intra-operative possible confounders were type or URS, type of fragmentation device, operation time, intra-operative complications and a postprocedural stent placement. Postoperative possible confounders were the method of evaluation, the length of hospital stay, retreatment, readmission and postoperative complications.

Statistical analysis {#Sec6}
--------------------

Inverse-probability-weighted regression adjustment (IPWRA) analyses were performed to determine whether there was a difference in SFR between using and not using of a UAS, independent from well-known possible confounders. Inversed probability weighting (IPW) is a method in which each observation is weighted by the propensity score of individual observations. If a subject had a higher probability of being in a group (using UAS or not), it was considered as overrepresented and therefore was given a lower weight. Alternatively, if the patient had a smaller probability of being in the group, it was considered as underrepresented and was given a higher weight. Generally, in an observational study, the weighting adjustment removes sampling bias \[[@CR9]\]. Subsequently, IPWRA is a regression analysis in which preoperative characteristics-based inverse probability weights are used in a regression model describing the relationship of interest.

Results {#Sec7}
=======

Patient characteristics {#Sec8}
-----------------------

A total of 2239 patients with renal stones were treated with flexible URS. Of these 1494 (67 %) patients were treated with the use of a UAS and 745 (33 %) without a UAS. Baseline characteristics are shown in Table [1](#Tab1){ref-type="table"}. Overall, subjects treated with an UAS have higher preoperative ASA scores and larger stones.Table 1Preoperative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of a ureteral access sheath (UAS)ParameterPatients treated with UAS\
(*n* = 1494)Patients treated without UAS\
(*n* = 745)Total population\
(*n* = 2239)Group difference statisticAge (years), mean (SD)51.2 (14.98)\
(*n* = 1494)50.2 (14.95)\
(*n* = 745)50.9 (14.98)\
(*n* = 2239)NSGender Male, *n* (%)901 (60.3)462 (62.0)1363 (60.9) Female, *n* (%)593 (39.7)\
(*n* = 1494)283 (38.0)\
(*n* = 745)876 (39.1)\
(*n* = 2239)NSBMI, mean (SD)27.8 (7.4)\
(*n* = 1398)27.4 (5.8)\
(*n* = 606)27.7 (6.93)\
(*n* = 2004)NSComorbidity, *n* (%) DM192 (12.9)\
(*n* = 1483)100 (13.7)\
(*n* = 729)292 (13.2)\
(*n* = 2212)NS CVD503 (34.0)\
(*n* = 1479)193 (26.5)\
(*n* = 729)696 (31.5)\
(*n* = 2208)NS Prednisone28 (1.9)\
(*n* = 1479)6 (0.8)\
(*n* = 730)34 (1.5)\
(*n* = 2208)NS Crohn's disease15 (1.0)\
(*n* = 1479)13 (1.8)\
(*n* = 731)28 (1.3)\
(*n* = 2210)NS Anticoagulation153 (10.4)\
(*n* = 1475)57 (7.8)\
(*n* = 729)210 (9.5)\
(*n* = 2204)NS Antibiotics1312 (88.8)\
(*n* = 1478)662 (91.7)\
(*n* = 722)1974 (89.7)\
(*N* = 2200)NSRenal stone location, *n* (%) Upper pole115 (7.9)63 (8.6)178 (8.1)NS Mid pole118 (8.1)78 (10.6)196 (9.0) Lower pole505 (34.9)271 (36.8)776 (35.5) Renal pelvis253 (17.5)130 (17.7)383 (17.5) Multiple458 (31.6)\
(*n* = 1449)194 (26.4)\
(*n* = 722)652 (29.8)\
(*n* = 2082)Stone size, *n* (%) \<10 mm720 (51.9)458 (65.8)1178 (56.6)*P* \< 0.01 ≥10 mm666 (48.1)\
(*n* = 1386)238 (34.2)\
(*n* = 696)904 (43.4)\
(*n* = 2082)Stone burden, mean (SD)^a^108.3 (114.4)\
(*n* = 1287)99.2 (100.5)\
(*n* = 658)102.2 (109.6)\
(*n* = 1945)NSPrevious calculus treatment, *n* (%)765 (51.8)\
(*n* = 1476)316 (42.8)\
(*n* = 739)1081 (48.8)\
(*n* = 2215)NS PCNL206 (14.0)\
(*n* = 1476)58 (7.8)\
(*n* = 738)264 (11.9)\
(*n* = 2218) SWL408 (27.7)\
(*n* = 1473)163 (22.1)\
(*n* = 738)571 (25.8)\
(*n* = 2211) Ureterolithotomy11 (0.7)\
(*n* = 1479)10 (1.3)\
(*n* = 741)21 (0.9)\
(*n* = 2220) URS384 (26.0)\
(*n* = 1475)168 (22.6)\
(*n* = 742)552 (24.9)\
(*n* = 2217) Pyelolithomy25 (1.7)\
(*n* = 1484)10 (1.3)\
(*n* = 742)35 (1.6)\
(*n* = 2226) UPJ pyeloplasty12 (0.8)\
(*n* = 1479)4 (0.5)\
(*n* = 740)16 (0.7)\
(*N* = 2222)Solitary kidney46 (3.1)\
(*n* = 1482)19 (2.6)\
(*n* = 740)65 (2.9)\
(*n* = 2222)NSRenal congenital abnormality, *n* (%)105 (7.0)40 (6.4)145 (6.5)NS Horse shoe18 (1.2)4 (0.5)22 (1.0) Ectopic4 (0.3)4 (0.5)8 (0.4) Malrotation4 (0.3)\
(*n* = 1490)3 (0.4)\
(*n* = 741)7 (0.3)\
(*n* = 2231)Preoperative stent, *n* (%)533 (35.8)284 (38.4)816 (36.7)NS Double J511 (95.9)278 (98.2)789 (96.7) Single J8 (1.5)--8 (1.0) Ureteric catheter3 (0.6)\
(*n* = 1487)2 (0.7)\
(*n* = 739)5 (0.6)\
(*n* = 1432)ASA score, *n* (%) I512 (36.4)267 (41.4)779 (38.0)*P* ≤ 0.01 II649 (46.2)266 (41.2)915 (44.6) III228 (16.2)105 (16.3)333 (16.2) IV16 (1.1)\
(*n* = 1405)7 (1.1)\
(*n* = 645)23 (1.1)\
(*n* = 2050)Case volume, *n* (%) Low-volume center314 (21.0)149 (20.0)463 (20.7)NS High-volume center1180 (79.0)\
(*n* = 1487)596 (80.0)\
(*n* = 745)1776 (79.3)\
(*n* = 2082)Sample sizes for which data were available are shown in parenthesisGroup differences were tested with a *t* test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables*BMI* body mass index, *DM* diabetes mellitus, *CVD* cardiovascular disease, *PCNL* percutaneous nephrolithotomy, *SWL* extracorporeal shockwave lithotripsy, *URS* ureteroscopy, *UPJ* ureteropelvic junction, *ASA* American Society of Anesthesiologists^a^Stone burden was calculated as the sum of all stone sizes (length × width × 0.25 × 3.14159)

Additionally, the UAS was most often used in North America (71.9 %), and South America (76.1 %), compared with Asia (67.3 %), Western Europe (66.1 %) and Eastern Europe (58.3 %). Systematic use (≥80 % of the procedures) of a UAS occurred in 39 centers (47 %), and never in 14 centers (17 %).

Operating parameters {#Sec9}
--------------------

Intra-operative characteristics are shown in Table [2](#Tab2){ref-type="table"}. More patients were treated flexible URS alone in the UAS group and more patients with flexible plus semirigid URS in the non-UAS group. Also, size of the stones is larger in the UAS group, complication rates differ between the groups, and operating time is longer in the UAS group. Laser fragmentation was the most common form of stone disruption used.Table 2Intra-operative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of a ureteral access sheath (UAS)ParameterPatients treated with UAS\
(*n* = 1494)Patients treated without UAS\
(*n* = 745)Total population\
(*n* = 2239)Group difference statisticType of URS, *n* (%)*P* \< 0.01 Flexible973 (65.1)416 (55.8)1389 (62.0) Flexible + semirigid521 (34.9)\
(*n* = 1494)329 (44.2)\
(*n* = 745)552 (38.0)\
(*n* = 2239)Fragmentation device, *n* (%) Laser1304 (87.9)609 (82.2)1913 (86.0)NS Other13 (0.8)16 (2.1)29 (1.3) None167 (11.3)\
(*n* = 1484)116 (15.7)\
(*n* = 741)283 (12.7)\
(*n* = 2225)Operating time (mins, mean \[SD\])80.0 (44.2)\
(*n* = 1414)64.7 (37.3)\
(*n* = 722)74.8 (42.6)\
(*n* = 2136)*P* ≤ 0.01Stone size sub-categories, *n* (%)*P* ≤ 0.01 \<10 mm720 (51.9)458 (65.8)1178 (56.6) ≥10 mm666 (48.1)\
(*n* = 1386)238 (34.2)\
(*n* = 696)904 (43.4)\
(*n* = 2082)Intra-operative complication, *n* (%)NS Uneventful1402 (94.1)706 (94.9)2108 (94.4) Failed12 (0.8)13 (1.7)25 (1.1) Bleeding31 (2.1)9 (1.2)40 (1.8) Perforation17 (1.1)9 (1.2)26 (1.2) Other5 (1.0)10 (1.3)30 (1.3) Converted3 (0.2)1 (0.1)4 (1.2) Avulsion--\
(*n* = 1490)−\
(*n* = 744)--\
(*n* = 2234)Postoperative stent, *n* (%)1352 (90.6)\
(*n* = 1493)611 (82.0)\
(*n* = 745)1963 (87.7)\
(*n* = 2238)NSSample sizes for which data were available are shown in parenthesisGroup differences were tested with a *t* test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables

Postoperative outcome and complications are shown in Table [3](#Tab3){ref-type="table"} {#Sec10}
---------------------------------------------------------------------------------------

Stone-free rates were 73.3 versus 59.3 % for the smaller stones and 81.5 versus 84.9 % for larger stones with and without a UAS, respectively; SFRs were lower with the use of a UAS (73.9 vs. 82.8 %). Higher SFR is most outspoken in cases with multiple stone locations. Also, hospital stay is longer in cases treated with an UAS.Table 3Postoperative characteristics of patients with renal stones treated with a flexible ureteroscopy (URS) with or without the assistance of a ureteral access sheath (UAS)ParameterPatients treated with access sheath\
(*n* = 1494)Patients treated without access sheath\
(*n* = 745)Total population\
(*n* = 2239)Stone-free rate, *n* (%)1051 (73.9)\
(*n* = 1422)602 (82.8)\
(*n* = 727)1653 (78.0)\
(*n* = 2149)*P* \< 0.01SFR by location sub-categories, *n* (%): Upper pole84 (76.4)52 (83.9)136 (79.0)NS Mid pole97 (84.3)69 (89.6)166 (86.5)NS Lower pole386 (79.8)222 (82.8)608 (80.9)NS Renal pelvis188 (78.3)102 (82.9)290 (79.9)NS Multiple263 (61.3)\
(*n* = 1018)148 (79.0)\
(*n* = 593)411 (66.7)\
(*n* = 1611)*P* \< 0.01SFR by stone size sub-categories, *n* (%) \<10 mm118(73.3)269 (59.3)387 (62.9)NS ≥10 mm712 (81.5)\
(*n* = 830)444 (84.9)\
(*n* = 713)1156 (82.7)\
(*n* = 1543)*P* ≤ 0.01Method of evaluation, *n* (%)NS Ultrasound572 (38.8)331 (44.7)903 (40.7) X-ray/KUB724 (49.1)285 (38.5)1009 (45.5) CT292 (19.8)83 (11.2)375 (16.9) IVU81 (5.5)20 (2.7)101 (4.6) Retrograde pyelogram20 (1.4)66 (8.9)86 (3.9) Intra-operative confirmation246 (16.7)99 (13.4)345 (15.6) Other16 (1.1)4 (0.5)20 (0.9) None142 (9.6)\
(*n* = 1476)29 (3.9)\
(*n* = 741)171 (7.7)\
(*n* = 2217)Hospital stay (d), mean (SD)1.47 (2.24)\
(*n* = 1481)1.69 (2.92)\
(*n* = 738)1.55 (2.48)\
(*n* = 2219)*P* = 0.025Retreatment, *n* (%)142 (9.5)\
(*n* = 1494)60 (8.1)\
(*n* = 743)202 (9.0)\
(*n* = 2237)NSPostoperative complication, *n* (%)102 (6.8)\
(*n* = 1494)40 (5.4)\
(*n* = 745)142 (6.8)\
(*n* = 2239)NSComplication according to stone location sub-categories, *n* (%):NS Upper pole8 (7.1)5 (12.5)13 (8.6) Mid pole12 (10.7)4 (10.0)16 (10.5) Lower pole32 (28.6)12 (30.0)44 (28.9) Renal pelvis22 (19.6)10 (25.0)32 (21.1) Multiple38 (33.9)\
(*n* = 112)9 (22.5)\
(*n* = 40)47 (30.9)\
(*n* = 152)Complication according to stone size sub-categories:NS \<10 mm52 (48.6)24 (60.0)76 (51.7) ≥10 mm55 (51.4)\
(*n* = 107)16 (40.0)\
(*n* = 40)71 (48.3)\
(*n* = 147)Total postoperative complications*, n* (%)115 (7.7)40 (5.4)155 (6.9)*P* = 0.041 Bleeding9 (5.6)4 (8.7)13 (5.9) Fever46 (28.6)18 (39.1)64 (29.4) UTI30 (18.6)11 (23.9)41 (18.8) Bladder cramps13 (8.1)5 (10.9)18 (16.2) Lung embolism1 (0.6)--1 (0.5) CVA--1 (2.2)1 (0.5) Sepsis7 (4.3)7 (15.2)14 (6.4) Acute abdomen2 (1.2)--2 (0.9) Other53 (32.9)\
(*n* = 1491)11 (23.9)\
(*n* = 743)64 (29.4)\
(*n* = 2234)Readmission \<3 months\
*n* (%)180 (13.1)\
(*n* = 1372)63 (9.1)\
(*n* = 693)243 (11.8)\
(*n* = 2065)NSSample sizes for which data were available are shown in parenthesisGroup differences were tested with a *t* test for continuous variables, a Chi-square test for dichotomous and an ANOVA for categorical variables*CT* computed tomography, *KUB* kidneys, ureters and bladder, *IVU* intravenous urography, *UTI* urinary tract infection, CVA cardiovascular accident

Regression analysis {#Sec11}
-------------------

Of the total study population, only those who had complete information (*n* = 1827) were used in the regression analysis. The IPWRA analyses based on both treatment and outcome models are shown in Table [4](#Tab4){ref-type="table"}. In this model, it was found that if none of the URS procedures were performed with the use of an UAS, the average stone-free rate would be 0.504, i.e., as much as 50 % of the population would be stone free. In addition, if all of the URS procedures were performed with the use of an UAS, the average stone-free rate would be 0.753, i.e., as much as 75 % of the population would be stone free. This difference of 25 %, however, representing the average treatment effect, was not significant (ATE: 0.248; *P* = 0.604). Using the IPWRA analysis on only the treated population in the estimations revealed no significant difference between using and not using of a UAS (31 %; ATET: 0.311; *P* = 0.523).Table 4Results of the inverse-probability-weighted regression adjustmentStone-free statusCoefficientSE*P* value95 % CIPotential outcome means (POM) AccSh  No (0) *A*0.5040.4780.291−0.432, 1.441  Yes (0) *B*0.7530.0120.0000.730, 0.776Outcome model (0) for the non-treated Operating time0.0000.0000.6200.000, 0.000 Intra-operative complications−0.3062.4680.901−5.143, 4.530 Postoperative complications0.8451.4830.569−2.062, 3.751 Constant−0.0352.0880.986−4.127, 4.056Outcome model (1) for the treated Operating time0.0000.0000.1190.000, 0.000 Intra-operative complications−0.2370.8420.779−1.887, 1.414 Postoperative complications−0.9570.8670.270−2.656, 0.742Constant1.1940.0690.0001.058, 1.329Treatment model Stone burden0.0000.0010.999−0.002, 0.002 Stone location0.0990.0390.0120.022, 0.176 Stone size0.0540.0280.059−0.002, 0.110 Previous treatment0.2010.1120.074−0.019, 0.420 Academic center−0.2520.1120.024−0.472, −0.033 Case volume−0.0020.0000.000−0.002, −0.001 Constant0.3700.2270.103−0.075, 0.815

Discussion {#Sec12}
==========

Flexible URS is currently recommended by the European Association of Urology Urolithiasis Guidelines for the treatment of renal stones sized up to 1.5 cm \[[@CR10]\]. Of note, currently most urologists recommend 'dusting' kidney stones when using flexible URS rather than fragmentation and removal of fragments, especially when treating larger sized stones. Consequently, one may question differences in outcome of SFR depending on the application of fragmentation or dusting of the stone. Whereas in smaller sized stones, depending on the localization and composition either dusting or fragmentation is used, in larger sized stones often the use of dusting followed by fragmentation is applied. At the very end, the SFR is based on the fragments left following fragmentation. An UAS can be most instrumental to remove the multitude of fragments.

Reports have been made that the use of the UAS impacts on SFRs following flexible URS. L'Esperance et al. \[[@CR1]\] conducted a retrospective review of 256 ureteroscopy procedures for the removal of renal calculi performed between 1997 and 2003 (173 with UAS and 83 without). The groups were similar in age, sex and stone burden. Overall SFRs were 79 and 67 % in the UAS group and non-UAS group, respectively (*P* = 0.042). In contrast, reports from Berquet et al. \[[@CR11]\] (86 % in UAS group vs. 87 % in non-UAS group; *n* = 280) and Kourambas et al. \[[@CR2]\] (78 % in the UAS groups vs. 85 % in non-UAS group; *n* = 59) reported no difference in SFRs with or without a UAS. In the current study with large patient population, SFR was 73.9 % in the UAS group versus 82.8 % in the non-UAS group. This indicates an UAS is not primarily used to increase SFR. However, there were a number of limitations to the study. One limitation is that the reason to use an UAS, such as fragments removal, facilitate access or decrease intra-renal pressure, was not recorded, and consequently, the primary reason for its use was unknown. Besides possible added efficacy of the use of an UAS, also the added safety of the use of an UAS without increased risk of ureteral damage is important. From Table [2](#Tab2){ref-type="table"} in the present work one can conclude that UAS usage did not increase the risk of ureteral damage (perforation 1.1 vs. 1.2 %) nor bleeding (2.1 vs. 1.2 %), whereas Table [3](#Tab3){ref-type="table"} shows the reduced incidence of postoperative infectious complications (fever, UTI, sepsis 28.6, 18.6 and 4.3 % vs. 39.1, 23.9 and 15.2 % for the UAS vs. the non-UAS group accordingly). Noteworthy is that several UAS are marketed involving different lengths, sizes and characteristics, which relate to ureter status and anatomy. A study on compatibility of the different UASs with flexible URS showed the 12/14 F UAS to be a "universal" UAS that accepts the currently available flexible ureteroscopes \[[@CR12]\]. But the smaller sized ureteroscopes have fueled the development of smaller sized UAS; at present 10/12 and 11/13 are predominantly used \[[@CR12]\], resulting in less complications.

Another limitation may be the evaluation of SFR. We are aware that standardization of evaluation of stone management is often lacking. This has been highlighted in a recent communication on standardization on terminology following PCNL \[[@CR13]\]. Ideally, a CT scan can best evaluate SFR following ureteroscopy. In the present real-life work, the SFR was evaluated by CT in a limited number of cases, whereas otherwise plain abdominal X-ray, renal ultrasound or intra-operative findings were used.

Finally, a more obvious limitation is the lack of randomization. As the subject characteristics between treatment groups (UAS or non-UAS) were imbalanced, the direct comparison of treatment groups was inappropriate. To overcome this, the IPWRA method \[[@CR14]\] was used to determine whether the use an UAS impacted on SFR and correcting this for intra- and postoperative characteristics. The results showed no significant difference in SFR between the using and not using of a UAS.

In conclusion, in the URS Global Study there was no difference in SFR when a UAS was used or not. This result was independent from baseline characteristics and corrected for possible intra- and postoperative confounders. Intra-operative complication rates were favorable for the UAS group, including less ureteral damage or bleeding.
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